Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
    • Collaborations
  • Platforms
    • About ADCs
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact
Dolasynthen, Other, Publications

Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug to Antibody Ratios

Dolasynthen, Publications, XMT-1660

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer

Dolasynthen, Publications, XMT-1660

XMT‑1660: A Phase 1b Trial of a B7‑H4–Targeting Antibody‑Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

Dolasynthen, Publications, XMT-1660

XMT-1660: A Phase 1b Trial of a B7-H4–targeting Antibody-Drug Conjugate (ADC) in Endometrial, Ovarian, and Breast Cancers

Dolasynthen, Publications, XMT-1660

Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer

April, 2022

Dolasynthen, Publications

Site Specific Dolasynthen ADCs Demonstrate Consistent Exposure Across a Wide Range of Drug-To-Antibody Ratios

October, 2021

Dolasynthen, Platform, Publications, XMT-1660

XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer

April, 2021

Dolasynthen, Other, Publications

XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma

June, 2020

Dolasynthen, Immunosynthen, Other, Publications

Mersana’s Innovative ADC Platforms – World ADC Summit 2019

October 2019

Dolasynthen, Other, Publications

Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform

April 2019

© 2023 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • ESG
    • Collaborations
  • Platforms
    • About ADCs
    • Dolasynthen
    • Immunosynthen
  • Pipeline
    • Overview
    • XMT-1660
    • XMT-2056
  • Publications
  • Investors & Media
    • Overview
    • Stock
    • Analysts
    • SEC Filings
    • News
    • Events
    • Annual Meeting
    • Governance
    • Quarterly Results
    • Contact Us
  • People
    • Culture
    • Benefits
    • Careers
  • Contact